Better Inputs, Better Outputs: High-Dimensional Data for Tomorrow’s RNA Medicines

28 Jan 2026
AI In Drug Discovery Stage
  • Eclipsebio performs sequencing-based measurements of RNA biology, including measurements of secondary structure and translation 

  • Their eVERSE portfolio supplies feature-rich, cell-specific RNA datasets that power smarter models for drug design 

  • Their validation assays close the loop, creating a unified workflow from discovery to regulatory filing 

Speakers
Wayne Doyle
Wayne Doyle, Associate Director, Head of Scientific Strategy - EclipseBio